5.3 Biochemical Recurrence & Salvage Therapies

5.3 Biochemical Recurrence & Salvage Therapies

Approximately 20% to 40% of men treated with radical prostatectomy (RP) or definitive radiation therapy (RT) develop a rising serum prostate-specific antigen (PSA) during follow-up, an oncological entity known as Biochemical Recurrence (BCR). Biochemical recurrence precedes clinical radiological metastasis by an average of 5 to 8 years. For the European Board of Urology examination, candidates must master the distinct definitions of BCR following surgery versus radiation, understand modern molecular imaging restaging with PSMA-PET/CT, and evaluate evidence-based salvage therapeutic pathways.

---

1. Consensus Definitions of Biochemical Recurrence

Because the biological consequences of surgery and radiation differ fundamentally, their definitions of biochemical recurrence are distinct:

Post-Radical Prostatectomy BCR

• Common Convention: PSA ≥0.2 ng/mL with a confirmatory elevation is widely used, including in AUA guidance. EAU notes that no single definitive post-RP relapse threshold can be specified; confirmed rises below this level may warrant early salvage assessment.
• Pathophysiology: Following complete surgical removal of the prostate and seminal vesicles, healthy and malignant prostate epithelial cells are extirpated. PSA should become undetectable after recovery, usually by around two months, with the reported threshold depending on the assay. Persistent measurable PSA and a later rise after an undetectable nadir are distinct patterns. Repeat testing and the trend help interpretation; PSA alone does not locate the residual or recurrent tissue.

Post-Radiotherapy BCR (Phoenix Consensus Definition)

• Definition: PSA nadir + 2.0 ng/mL (measured at any time following radiotherapy, regardless of whether the patient received concurrent androgen deprivation therapy).
• Pathophysiology: Radiation therapy does not immediately ablate prostate tissue; rather, it induces mitotic cell death over months to years. Residual benign prostate parenchyma continues to secrete low levels of PSA, achieving a lowest post-treatment level known as the PSA nadir (which may take three years or longer). The Phoenix threshold defines biochemical failure and correlates with clinical outcomes; it does not by itself prove the site or histology of recurrence.

Risk Stratification of BCR: PSA Kinetics

Not all biochemical recurrences have the same prognosis. EAU uses different risk rules after surgery and radiotherapy:

• After RP: Low risk means PSADT >1 year AND pathological GG<4; high risk means PSADT≤1 year OR pathological GG4–5.
• After RT: Low risk means interval to biochemical failure >18 months AND biopsy GG<4; high risk means interval≤18 months OR biopsy GG4–5. These groups guide counselling, monitoring and salvage decisions. There is no additional universal three-year cutoff in these definitions; high-risk recurrence requires timely individualized assessment rather than automatic treatment of every PSA rise.

---

2. Molecular Restaging: PSMA-PET/CT

Restaging can distinguish prostatic-bed, nodal and distant recurrence and change treatment fields. It is particularly important before invasive post-RT local salvage; post-RP bed SRT can still be indicated when microscopic recurrence is not visible.

Limitations of Conventional Imaging

Conventional imaging modalities—technetium-99m bone scintigraphy and contrast-enhanced CT of the abdomen and pelvis—have exceptionally low diagnostic yield in early biochemical recurrence. EAU reports a positive bone-scan probability <5% when PSA is <7 ng/mL in PSA-only recurrence after RP, and positive CT findings in only 11–14% of BCR patients. CT positivity in a cohort is not the same as sensitivity for normal-sized metastatic nodes.

Prostate-Specific Membrane Antigen (PSMA) PET/CT

PSMA is a transmembrane glycoprotein overexpressed up to 1,000-fold on prostate cancer cell membranes. Radiotracers targeting PSMA—such as 68Ga-PSMA-11, 18F-DCFPyL, and 18F-PSMA-1007—have revolutionized restaging. Prospective recurrent-disease studies show useful localization at PSA levels where conventional imaging is often negative. proPSMA studied initial high-risk staging, not BCR. Detection varies with PSA, tracer and population; a prospective 635-patient 68Ga-PSMA-11 study reported:

• PSA <0.5 ng/mL: 38% positive.
• PSA 0.5–<1.0: 57%.
• PSA 1.0–<2.0: 84%.
• PSA 2.0–<5.0: 86%, and ≥5.0: 97%. These are study detection rates, not guaranteed sensitivity or proof that a negative scan excludes cancer.

---

3. Salvage Radiotherapy (SRT) Post-Prostatectomy

Salvage radiation therapy directed to the prostatic bed (with or without elective pelvic nodal irradiation) is the principal established treatment offering potential cure for a presumed local recurrence after prostatectomy.

Timing & Dose of Salvage Radiotherapy

• Early Initiation: Lower pre-SRT PSA is associated with better control. Treat promptly once SRT is chosen, commonly before PSA exceeds 0.5 ng/mL, rather than waiting to reach a fixed threshold. Outcome also depends on grade, stage, PSA kinetics and treatment; there is no universal 10% loss of control for each 0.1 ng/mL increase.
• Dose: EAU recommends at least 64 Gy to the bed, using modern conformal planning; doses around 64–70 Gy are used according to context. A mandatory minimum of 66–70 Gy is incorrect, and escalating dose can increase toxicity.

Addition of Concurrent Androgen Deprivation Therapy

The trials used different drugs, durations and endpoints:

1. GETUG-AFU16: SRT 66 Gy with or without six months of goserelin, for rising PSA after RP. Ten-year progression-free survival improved (64% versus 49%); an overall-survival benefit was not demonstrated.
2. RTOG9601: SRT 64.8 Gy with or without 24 months of bicalutamide 150 mg/day. Overall survival improved in the trial population. A secondary analysis found no OS benefit and more other-cause mortality/toxicity at pre-SRT PSA ≤0.6 ng/mL; this cannot be equated to six-month GnRH therapy.

• Practice: EAU weakly recommends offering hormonal therapy with SRT. Discuss benefit, recurrence risk and adverse effects rather than requiring six months for everyone. Short courses of 4–6 months and longer courses in selected higher-risk patients have different evidence; RADICALS-HD found better MFS with 24 versus 6 months, with more prolonged toxicity. SRT alone remains appropriate for selected lower-risk patients.

Adjuvant vs Early Salvage Radiotherapy Controversy

Adverse pathology previously led to routine immediate ART. RADICALS-RT, RAVES and GETUG-AFU17, combined in ARTISTIC, support PSA monitoring with an early-SRT policy for many men whose postoperative PSA is undetectable: five-year EFS was 89% with ART versus 88% with early-SRT policy, without significant evidence of benefit from ART, and only 39% of the salvage-policy group had needed RT at analysis. This is not proof of identical EFS/MFS for every subgroup. EAU still weakly recommends ART for pN0, GG4–5, pT3 with or without positive margins. Distinguish postoperative monitoring from AS for an untreated prostate.

---

4. Local Salvage Therapies Following Radiation Failure

When a patient develops biochemical recurrence following primary external beam radiotherapy or brachytherapy (Phoenix definition: nadir + 2.0 ng/mL), systemic treatment is not automatic. EAU advises against ADT for M0 recurrence with PSADT >12 months. For EMBARK-like high-risk BCR (conventionally M0, PSADT ≤9 months, PSA ≥1 ng/mL after RP or ≥2 ng/mL above the post-RT nadir), offer enzalutamide plus ADT when systemic salvage is appropriate. For a carefully selected subgroup with true isolated, histologically confirmed intraprostatic recurrence, local salvage therapy offers potential long-term cure.

Mandatory Pre-Requisite Staging for Local Salvage

Before contemplating invasive salvage local therapies, the clinician should:

1. Assess original stage/grade, PSA, recurrence interval, functional status and whether a curative salvage procedure is realistic; a longer interval is favourable rather than a universal mandatory >2–3-year requirement.
2. Confirm life expectancy >10 years and a low comorbidity burden.
3. Obtain histological confirmation of viable recurrence via transperineal/transrectal prostate re-biopsy.
4. Exclude visible nodal/distant metastases with appropriate staging, usually PSMA-PET/CT. Prostate MRI helps localize and target biopsy; negative imaging cannot exclude microscopic disease.

Local Salvage Modalities & Complication Profiles

• Salvage Radical Prostatectomy (SRP): Complete excision of the irradiated prostate. Oncologically potent (5-year BCR-free survival 45–60%), but technically formidable due to radiation-induced endarteritis obliterans, marked tissue fibrosis, and obliteration of normal planes. Morbidity is severe: urinary incontinence rates of 40% to 70%, bladder neck contracture/stricture in 25% to 40%, rectal injury/rectourethral fistula in 5% to 10%, and near-universal erectile dysfunction.
• Salvage Cryotherapy: Transperineal cryoablation using argon gas freezing cycles to achieve temperatures of -40°C. Lower operative morbidity than SRP, but causes urinary sloughing, urethral stricture (10–15%), and rectourethral fistula (1–3%).
• Salvage Brachytherapy: Interstitial HDR or LDR brachytherapy delivers targeted focal or whole-gland re-irradiation. Produces 5-year biochemical control of 50–65%, with severe late grade 3 genitourinary/gastrointestinal toxicity of 5% to 15%.
• Salvage HIFU: Acoustic thermal ablation can cause incontinence, obstruction and fistula. EAU restricts salvage HIFU and cryotherapy to selected patients in clinical trials or well-designed prospective cohorts; salvage RP, brachytherapy or SBRT also require careful selection in experienced centres.

---

5. Biochemical Recurrence & Salvage Decision Matrix